Introduction {#sec1}
============

Influenza A virus (IAV) causes the flu and poses a serious threat to human health. History has shown that the flu can lead to serious pandemics, with millions of deaths in 1918^[@ref1]^ and a risk of future outbreaks of deadly variants.^[@ref2]^ IAV contains two envelope glycoproteins that bind to sialylated glycans. The hemagglutinin (HA) is responsible for attachment of the virus to the tissue surface to be infected, and its specificity lies at the origin of the species specificity and tissue tropism of the virus, while it is also of importance for the viral fusion with the endosome.^[@ref3]^ The neuraminidase (NA) is a glycosidase enzyme that removes the sialic acid group from glycans which leads to a release of the HA-based attachment^[@ref4]^ and allows the virus to burrow through the protective mucosa and enter the cell. Importantly, the NA also allows the progeny virions to be released from the cell surface to infect other cells. A functional balance is needed between the binding and cleavage properties of NA and HA.^[@ref4]−[@ref6]^

IAVs cause seasonal epidemics and occasional pandemics. The latter are caused by animal viruses that managed to cross the animal--human species barrier. Prophylactic and therapeutic options against influenza are limited. Several approaches are being used, the most common of which is the vaccination strategy. This is a valuable approach for the seasonal IAV variants that are very common and infective, yet usually only life threatening for those with weakened immune systems. Vaccination is complicated by the large antigenic variation in HA and NA with currently 16 HA and 9 NA subtypes of varying antigenicity known.^[@ref3]^ Also within HA and NA subtypes changes in antigenicity resulting from mutational variation (antigenic drift) are observed. Nevertheless recent progress was reported toward prophylactic and therapeutic vaccines.^[@ref7]^ In case of an epidemic, neuraminidase inhibitors such as oseltamivir or zanamivir can be used to reduce the illness symptoms and infectivity.^[@ref8]^ Unfortunately, resistance of IAV to these neuraminidase inhibitors has been observed^[@ref9]^ which greatly hampers the effectiveness of the therapy. Similar to the approach to HIV infections, it will likely be more effective to use a combination therapy that addresses HA and NA and possibly additional targets.

While NA was proven to be a druggable target that yielded nanomolar inhibitors with improved glycomimetic and prodrug characteristics to overcome some of the challenges of carbohydrate drugs,^[@ref10]^ the situation is different for HA. The adhesion protein binds only with millimolar affinities to sialylated glycan receptors. Binding has been observed to α2,6-SiaLAcNAc for the human type specific HAs or α2,3-SiaLAcNAc for avian type-specific HAs.^[@ref5],[@ref11]−[@ref13]^ The low affinities are a challenging starting point for a carbohydrate based drug development program, but also non-carbohydrate approaches have faced this challenge.^[@ref14]^ The virus, however, binds with high affinity to tissue surfaces by using multivalency,^[@ref15]^ which increases its avidity to levels that enable infection. The multivalency effects involve the simultaneous binding of glycans to more than one of the three binding sites per HA trimer on the IAV surface but also the simultaneous binding of cell surface glycans to multiple HA protein trimers on the viral surface. The overall avidity effects are very strong^[@ref4]^ and crucial for IAV. In that sense it is a logical step to attempt to block the viral infection via the HA protein with a multivalent inhibitor.

We here describe our use of di- and trivalent scaffolds as multivalent scaffolds to inhibit IAV ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![(a) Top view of an X-ray structure of an HA trimer protein bound to three molecules of α-2,3-SiaLac (PDB code 1HGG).^[@ref11]^ (b) Schematic tripodal ligand design for the chelation type inhibition of influenza virus A hemagglutinin protein.](jm-2019-003037_0001){#fig1}

These scaffolds were extended with α2,6-SiaLacNAc linked to lactose. The largest of the compounds were larger (more atoms in the spacers between sialic acid units; see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf)) than a biantennary Sia(LacNAc)~3~ linked to a trimannose core, known for chelation.^[@ref16]^ The constructs were evaluated as inhibitors in a viral binding assay and were shown to be significantly stronger inhibitors than their monovalent counterparts, and they were hardly affected by neuraminidases. Finally, they were also shown to inhibit IAV infection.

Multivalency as a strategy to enhance binding and inhibition has been widely explored in protein--carbohydrate interactions^[@ref17],[@ref18]^ to bridge binding sites^[@ref19]^ or inhibit pathogen binding^[@ref20]^ by mechanisms such as chelation and statistical rebinding.^[@ref21],[@ref22]^ Indeed several examples of multivalent sialic acid containing glycans have been reported. Relatively large molecular entities can take advantage of their size to bridge multiple HA trimers.^[@ref23]^ Some of these have yielded potency enhancements of 3--4 orders of magnitude. Such systems include a polyacrylate carrier,^[@ref24]^ polyacrylamide,^[@ref25],[@ref26]^ polyglutamic acid,^[@ref27]^ polyglycerol based nanoparticles,^[@ref28],[@ref29]^ chitosan,^[@ref30]^ and liposomes.^[@ref31]^

For drug development it would be an advantage if monodisperse, small well-defined molecular entities can be used, with no risk of immunogenicity. Reaching this goal has proven considerably more difficult. Reported studies by Knowles et al. showed that certain divalent sialiosides,^[@ref32],[@ref33]^ did not exhibit enhanced HA binding when exposed to an HA trimer but were able to enhance hemagglutination inhibition when the HAs were present on a viral surface. Their convincing proof showed that the compounds were able to bridge between HA trimers, an aggregation mechanism, the benefits of which are not well understood.^[@ref19]^ Similar observations were made by others including a system containing two α-2,6-SiaLacNAc units linked via a single galactoside moiety,^[@ref34]^ dendrimers presenting sialic acids,^[@ref35]^ cyclic peptides presenting sialyl lactosides,^[@ref36]^ and a calixarene linked to four sialic acids.^[@ref37]^ These constructs resulted in moderate enhancements, and they did not have the structural features now known to be needed to bridge between binding sites within an HA trimer (∼67 atoms in the bridge between sialic acids).^[@ref16]^ An interesting case is a system based on a trisubstituted benzene ring linked to sialic acids via peptidic spacer arms. This construct with the right dimensions to bridge binding sites was reported to bind to immobilized HA by SPR with a *K*~d~ of 450 nM.^[@ref38]^ However, the peptidic component showed significant binding indicative of peptide protein interactions but indeed leading to an overall potent compound. In another system, a three-way junction DNA for the display of α-2,3-SiaLac units was shown to be potent, but a single arm was not much less potent. This is indicative of DNA--protein interactions and makes a bridging mechanism less likely.^[@ref39]^ A system based on PNA-DNA complexes displaying two α-2,6-SiaLacNAc units at various distances was also reported.^[@ref12]^ Evidence for true chelation, i.e., bridging between binding sites, was provided and yielded a ∼30-fold enhancement (15-fold per sugar) over a DNA-PNA reference construct containing only a single glycoligand. Unfortunately, these noncovalent constructs of ∼21 kDa are not small molecules. Other indications that chelation of HA binding sites is indeed possible come from carbohydrate array experiments with biantennary glycans. They showed that glycans with at least three LacNAc units in each of the arms bound more strongly to human type specific HAs.^[@ref16]^ Molecular modeling supported the chelation mode and indicated that two LacNAc units would be too short. This chelation type binding was shown to only be possible for the human type specific HA binding to α2,6-linked sialic acid for geometrical reasons and is precluded for the α2,3-linked ones.^[@ref6]^

On the basis of these clear indications that chelation is possible, we directed our efforts to make di- and trivalent ligands for the HA protein of IAV that can engage more than one of its three binding sites at the same time.

Results {#sec2}
=======

The synthesis started with the preparations of the building blocks shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. Their detailed syntheses can be found in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf). Compounds **1**--**3** are the core or scaffold structures outfitted with azido groups. The other compounds **4**--**8** are the glycans that contain alkyne groups for linkage to **1**--**3** by CuAAC conjugation. Compound **1** represents a trivalent scaffold derived from a known triamine^[@ref40]^ with the potential to display three glycans toward all three HA binding sites of the trimer. Compound **2** is a divalent spacer with rigid elements such as a direct linkage between glucose and triazole, a motif that was previously explored in rigid spacers for enhanced multivalency effects.^[@ref41]−[@ref43]^ Compound **3** is a polymeric dextran scaffold^[@ref44]^ for comparison with the "small" molecule scaffolds **1** and **2**. Compounds **4**, **5**, and **8** were made from propargyl lactose, and **7** was made from LacNAc, and azidolactose and 1,4-diethynylbenzene were the starting materials for **6** via CuAAC. The β1,3-linked GlcNAc and β1,4-linked Gal moieties of **5**, **6**, and **8** were introduced using glycosyl transferases. Similarly, the α-2,6-linked sialic acid part of **7** and **8** was added using a sialyl transferase.

![Structures of the building blocks used in the synthesis of the multivalent carbohydrate HA inhibitors.](jm-2019-003037_0002){#fig2}

The alkyne-linked lactose/LacNAc building blocks **4a**, **5**, and **6** were coupled to the azido scaffolds **1** and **2** via CuAAC conjugation as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The products were purified and in one case deprotected (synthesis of **9**) before the final sialylation with the sialyltransferase enzyme PmSTI mutant, which was mutated to achieve the desired 2,6 specificity.^[@ref45]^ The products were purified by preparative HPLC to yield the fully sialylated **10**, **12**, **14**, and **17**.

![Synthesis of Multivalent HA Inhibitors\
Reagents and conditions: (a) CuSO~4~·5H~2~O, Na ascorbate, DMF/H~2~O (9:1), microwave, 80 °C; (b) NaOMe, MeOH; (c) CMP-NANA, PmSTI mutant.](jm-2019-003037_0005){#sch1}

In the sialyation of **13** also the disialylated **15** was obtained and purified as a useful reference compound. In our hands, performing the CuAAC conjugation with the sialylated building blocks such as **7** and **8** was problematic, which is the reason for the strategy of performing the sialylation as the last step on the multivalent precursor.

The inhibition studies were conducted with the use of a biolayer interferometry (BLI) assay.^[@ref4]^ In this assay a streptavidin coated sensor was loaded with a sialylated glycoprotein LAMP1. Influenza A virus WU95 (containing a H3 protein of a human H3N2 virus; see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf)) was used, and its binding to the sensor could readily be observed. Performing the experiment in the presence of the inhibitors clearly showed inhibition ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a). By use of a range of concentrations for each compound, inhibition curves were obtained ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B) and the results were quantified ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

![(a) Analysis of inhibition of virus-receptor binding by BLI. Real-time kinetic analysis of virus binding to LAMP1 was performed by BLI. A representative experiment of concentration-dependent inhibition of virus binding by **15** is shown as determined by the BLI wavelength shift. (b) Inhibition curves of compounds from left to right, **14** (blue), **15** (red, obstructed by **14**), **18** (purple), **12** (green), **17** (yellow), **10** (orange), **8** (brown), and **7** (light purple), of the virus-receptor binding determined similarly as shown in (a).](jm-2019-003037_0003){#fig3}

###### Results of IAV Inhibition by Multivalent Carbohydrates Using BLI and HAI Assays

  entry   construct   glycoligand                valency   IC~50~ BLI (μM)[d](#t1fn4){ref-type="table-fn"}   rel pot. (per sugar)[a](#t1fn1){ref-type="table-fn"}   *K*~i~ HAI (μΜ)                      rel pot. (per sugar)[b](#t1fn2){ref-type="table-fn"}
  ------- ----------- -------------------------- --------- ------------------------------------------------- ------------------------------------------------------ ------------------------------------ ------------------------------------------------------
  1       **7**       SiaLacNAc                  1         304 ± 11                                          1 (1)                                                  nd[c](#t1fn3){ref-type="table-fn"}    
  2       **8**       SiaLacNAcLac               1         396 ± 3                                           1 (1)                                                  360 ± 139                            1 (1)
  3       **13**      LacNAcLac-triazole-Ph      3         no inhib at 20 μM                                                                                        nd[c](#t1fn3){ref-type="table-fn"}    
  4       **10**      SiaLac                     3         15 ± 0.3                                          20 (7)                                                 53 ± 15                              7 (2)
  5       **17**      SiaLac                     2         13 ± 1                                            23 (12)                                                nd[c](#t1fn3){ref-type="table-fn"}    
  6       **12**      SiaLacNAcLac               3         4.3 ± 3.7                                         71 (24)                                                nd[c](#t1fn3){ref-type="table-fn"}    
  7       **14**      SiaLacNAcLac-triazole-Ph   3         0.71 ± 0.08                                       428 (143)                                              9.4 ± 3.8                            38 (13)
  8       **15**      SiaLacNAcLac-triazole-Ph   2         0.71 ± 0.15                                       428 (214)                                              10.3 ± 5.6                           35 (17)
  9       **18**      SiaLacNAc                  55        1.51 ± 0.16                                       201 (4)                                                3.75 ± 1.4                           96 (2)

Relative to the potency of **7**.

Relative to the potency of **8**.

Not determined.

in the presence of 10 μM oseltamivir carboxylate.

First to note is that the inhibition with the two reference compounds **7** and **8** showed relatively low IC~50~'s below the millimolar level that is commonly associated with the binding of sialic acid derivatives to whole virus or HA. Another notable fact is that the inhibition of the two compounds is very similar, indicating that the added lactose moiety of **8** does not help the binding. Another reference compound was **13**. It contains the triphenylbenzene core linked to the LacNAcLac arms. The combined presence of the hydrophobic aromatic core and the 12 sugar moieties did not yield any detectable inhibition in the assay up to the 20 μM used in the assay.

Compounds **14** and **15** were the most potent in the assay, with IC~50~ of 0.7 μM, representing a 428-fold enhancement over reference **7**. The two compounds were strikingly similar in the assay, clearly indicating that two sialic acid groups were sufficient and that simultaneous binding to all three HA sites with **14** was not achieved. The fact that both compounds were similar indicates that the expected statistical advantage of **14** is compensated by other factors. The trivalent compounds with the shorter linker **12** and shorter ligand moieties **10** were considerably weaker inhibitors with IC~50~ of 4.3 and 15 μM, respectively, indicating the importance of the length of the arm. The divalent scaffold **2** contains a similar number of atoms separating the azido groups as trivalent scaffold **1**. Notably, the compound based on **2**, i.e., **17**, had very similar potency when compared to the one derived from **1**, i.e., **10**. This result again indicates that divalent binding is likely. Furthermore, it indicates the importance of the length of the arm, as the longer arms lead to enhanced inhibition. Interestingly, the polymeric glycoconjugate **18**, while a potent inhibitor with an IC~50~ of 1.5 μM, was weaker than the tri- and divalent **14** and **15** and much more so when corrected for valency, as the relative potency per sugar is only 3.75.

In addition to BLI experiments with an H3-containing virus (WU95), we analyzed the inhibitory activity of **14** against another human virus (H1N1) and an avian H5N1 virus. The human H1N1 virus was efficiently and fully inhibited, although with a somewhat higher IC~50~ (2.7 μM) than the H3 containing virus. In contrast the avian H5N1 virus could be inhibited maximally 50%, which probably relates to differences in the receptor-binding properties of the different viruses. The fact that full inhibition of H5N1 was not achieved is likely caused by this virus preferring binding to α2,3- over α2,6-linked sialic acids, both of which are present on the glycoprotein receptor, while the inhibitor contains α2,6-SiaLAcNAc.^[@ref46]^

The above experiments were run in the presence of 10 μM neuraminidase inhibitor oseltamivir carboxylate (OC) to inhibit the neuraminidase that could potentially cleave off the sialic acid moieties from the inhibitors. A direct comparison was made between experiments involving inhibitory concentrations (3 μM) of **14**, **15**, and **12** in the presence of oseltamivir carboxylate, with the same experiments without the NA inhibitor. These experiments showed very similar degrees of inhibition. Repeating these experiments with a different IAV, i.e., VI75 (containing H3 from another H3N2 virus; see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf)), showed, first, similar degrees of inhibition and, second, no effect of oseltamivir carboxylate.

Besides the BLI assay, also a hemagglutination inhibition (HAI) assay was performed using the H3-containg WU95 virus for a number of our compounds. Results are shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Overall the results show the same trends but the *K*~i~'s for the most potent compounds **14** and **15** were not as low but still in the low micromolar range. It should be noted that the conditions are different in both assays, and especially multivalency effects can vary due to the in vitro assay conditions.^[@ref47]^ Notably the receptor density on red blood cells is considerably higher than present in the BLI assay.

To further evaluate the potential of the compounds as IAV inhibitors, an infection inhibition test was performed using the H3-containing WU95 virus. As such, MDCK-II cells were exposed to IAV at a multiplicity of infection (MOI) of 0.005 tissue culture infectious dose 50 (TCID~50~) per cell in the presence and absence of **14** or **12** at different concentrations without the presence of an NA inhibitor. At 7 h postinfection the number of infected cells were determined (see [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), and IC~50~ values were determined. In agreement with the BLI results, **14** (IC~50~ = 4.4 μM) inhibited infection more efficiently than **12** (IC~50~ = 15 μM). Furthermore, it was determined that the two compounds did not cause significant cytotoxicity (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf)). In addition, we analyzed the ability of the compounds to prevent cell killing by virus infection. Again, **14** was more effective than **12** (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf)). Finally, we analyzed whether synergy could be observed between HA inhibitor **15** and NA inhibitor oseltamivir carboxylate. Low nanomolar concentrations of each showed little effect, but when they were combined, a significant reduction of infection was observed (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf)).

![Infection of MDCK-II cells by H3-containing WU95 virus in the presence or absence of **14** and **12**. Inhibition of infection relative to infection in the absence of compounds is graphed.](jm-2019-003037_0004){#fig4}

Discussion and Conclusions {#sec3}
==========================

We here showed the successful synthesis of multivalent sialic acid containing glycoconjugates. Their synthesis was possible by a combination of chemical scaffold synthesis, enzymatic carbohydrate synthesis, and CuAAC conjugation. The well-defined systems were found to inhibit the binding of IAV in a dose dependent manner. Clearly a combination of structural features is needed for inhibition as a single sugar arm is weakly active and the non-sialyl system is not active. Enhancements of 428-fold were achieved with the system containing two or three sialic acid units. Furthermore, the use of divalent systems showed similar results to experiments performed with trivalent systems. Therefore, not all three binding sites can be occupied simultaneously by our system, but two seem possible, as previously indicated for large biantennary glycans^[@ref39]^ and DNA bridged divalent ligands.^[@ref12]^ The length of the glycan arm is an important factor in the potency.

Hemaglutination inhibition experiments gave the same trends as the BLI assay, but effects were smaller. A difference was seen in the degree of inhibition and multivalency effects. Overall the data are consistent with a bivalent chelating binding mode.^[@ref6],[@ref12],[@ref48]^ As such this is the first example of a nonmacromolecular compound to demonstrate this and indicates that with additional optimization a therapeutic avenue is within reach. Compounds **14** and **12** were tested in infection inhibition assays and cell killing inhibition assays. In both of these cases inhibition is clearly observed, and the order of potency is consistent with that from the BLI assay. Furthermore, no toxicity was observed for these compounds. In the BLI assay it was remarkable that no effect of the NA inhibitor oseltamivir carboxylate was observed. Furthermore, in the infection inhibition assay no NA inhibitor was added, yet full inhibition was observed. Others^[@ref38]^ have seen a similar nonresponse to NA blocking before and explained it with (1) the tight inhibitor binding to HA, resulting in less availability for NA, (2) weak inherent NA activity, especially on the α-2,6 isomers, and (3) a lower presence of NA compared to HA. For medical application of this type of NA inhibiting compound the introduction of an S-linked sialic acid, as previously reported,^[@ref49]^ is nevertheless recommended to ensure sialic acid cleavage from the inhibitor by NA does not happen. In agreement herewith, **15** showed a synergistic effect with NA inhibitor OC. Low nanomolar concentrations of either reagent had no major effect, but the combination greatly reduced infections. This result supports the notion of a combination therapy, as practiced for HIV. The multivalent approach as described here may not be limited to IAV but can likely be extended to other systems as previously shown for adenovirus.^[@ref50]^

Experimental Section {#sec4}
====================

Chemistry {#sec4.1}
---------

Compounds **2**,^[@ref42]^**3**,^[@ref51]^**4b**^[@ref52]^ and propargyl were synthesized as previously reported. Yields of individual reactions and spectra data are reported in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf). All tested compounds were \>95% pure by HPLC.

Tris-azide (**1**) {#sec4.1.1}
------------------

1,3,5-Tris(3-aminophenyl)benzene^[@ref40]^ (70 mg, 0.2 mmol) was dissolved in DCM (5 mL). 4-Azidobutanoic acid (77 mg, 0.6 mmol, 3 equiv) was added, followed by DMAP (7.3 mg, 0.06 mmol, 0.3 equiv), EDC·HCl (190 mg, 1.0 mmol, 5 equiv). The mixture was stirred for 48 h at room temperature. Then the solution was washed with 1 M HCl solution, followed by saturated NaHCO~3~ solution and by saturated NaCl solution. After drying (Na~2~SO~4~) the solvent was removed, and the residue was purified using column chromatography over silica gel (eluent DCM/MeOH 75:1 v/v) to give 55 mg (40%) of an off-white solid.

General Procedure for the Synthesis of LacNAc Sequences in **5** and **6** {#sec4.2}
--------------------------------------------------------------------------

The appropriate lactoside (1 equiv, ∼0.03 mmol) and UDP-GlcNAc (1.5 equiv) were dissolved in HEPES buffer (50 mM, pH 7.3, 2.5 mL) containing KCl (25 mM), MgCl~2~ (2 mM), and dithiothreitol (1 mM). To this, 20 μL of CIAP (10 mU) and 50 μL of *H. pylori* β3GlcNAcT (β1-3GlcNAc transferase) were added. The resulting reaction mixture was incubated at 37 °C for 14 h, followed by Biogel P-2 and silica gel (**6**) purification. The resulting GlcNAc glycan (0.007--0.017 mmol, 1 equiv) and UDP-Gal (1.5 equiv) were dissolved in MES buffer (100 mM, 300--500 μL) containing MnCl~2~ (20 mM). To this, 30--50 μL of LgtB (β1-4Gal Transferase) was added. The resulting reaction mixture was incubated at 37 °C for 3 h. The reaction mixture was centrifuged, and the supernatant was purified by gel filtration over Biogel P-2 (eluent H~2~O).

General Procedure for the Enzymatic 2,6-Sialylation in the Synthesis of **7**, **8**, **10**, **12**, **14**, **15**, and **17** {#sec4.3}
--------------------------------------------------------------------------------------------------------------------------------

The appropriate LacNAc derivative (1 equiv) and CMP-NANA (1.2--3.3 equiv per LacNAc unit) were dissolved in Tris-HCl buffer (100 mM, pH 7.5, 200--500 μL) containing MgCl~2~ (20 mM). To this, PmST1 mutant P34H/M144L (α2-6 sialyltransferase, 20--50 μL) was added to the reaction mixture. Then the resulting reaction mixture was incubated at 37 °C for 4 h. The reaction mixture was centrifuged and the supernatant subjected to gel filtration over Biogel P-2 (eluent H~2~O). Fractions containing product were combined and lyophilized for further preparative HPLC (HILIC column) for **12**, **14**, **15**, and **16**.

General Procedure for CUAAC Conjugation in the Synthesis of **9a**, **11**, **13**, **16** {#sec4.4}
------------------------------------------------------------------------------------------

The appropriate azido compound (1 equiv) and alkyne (1.3--2.3 equiv per azido group), CuSO~4~·5H~2~O (0.04--0.5 equiv), sodium [l]{.smallcaps}-ascorbate (2.5 equiv) were dissolved in DMF/H~2~O (0.2--2 mL). The reaction was performed under microwave irradiation (80--100 °C, 1--1.5 h). Then the mixture was concentrated in vacuo. The residue was purified by silica chromatography (DCM/MeOH 20:1 v/v) for **9a** and Biogel P-2 (eluent H~2~O) for the others.

Polymer **18** {#sec4.4.1}
--------------

The azido polymer (**3**) was dissolved in water followed by the addition of **7** (3 mg, 1.3 equiv). CuSO~4~·5H~2~O (0.1 equiv) and sodium [l]{.smallcaps}-ascorbate (0.3 equiv) were dissolved in water separately and added to the reaction mixture. The reaction was carried out at 100 °C with microwave radiation for 60 min. The solvent was evaporated, and the crude reaction mixture was purified by dialysis using a cellulose based dialysis cassette (MWCO: 2K) against deionized water for 3--4 days and freeze-dried to give a white compound (3 mg, 24%). The disappearance of the azide stretching peak in the IR spectra of the final compound confirmed that all of the azido groups had reacted.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.jmedchem.9b00303](http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b00303).Experimental details of the synthesis, characterization, and compound evaluation ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf))Molecular formula strings and some data ([CSV](http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_002.csv))
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